Mayon Ashton
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,879 of the $3,379 with a category attached, or 85.2%. It is spread thinly across 20 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,478, 3.0 times the $500 reported in 2023.
Across 84 payments — averaging $40.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$561
- AstraZeneca$551
- Veloxis Pharmaceuticals, Inc.$500
- Corcept Therapeutics$409
- Renalytix AI, Inc.$253
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$194
- plus $910 from 14 others
What the payments were for
- Consulting fees$50015%
- Food & beverage$2,87985%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $561 |
| AstraZeneca | 12 | $551 |
| Veloxis Pharmaceuticals, Inc. | 1 | $500 |
| Corcept Therapeutics | 10 | $409 |
| Renalytix AI, Inc. | 6 | $253 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $194 |
| Astellas Pharma US Inc | 3 | $143 |
| Axsome Therapeutics, Inc. | 2 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 2 | $95 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $69 |
| GSK | 2 | $53 |
| Pfizer | 3 | $51 |
| Novartis | 2 | $50 |
| Dexcom, Inc. | 3 | $49 |
| Lilly USA, LLC | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| Phadia US Inc. | 1 | $20 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Envarsus$500
- Korlym$332
- AIRSUPRA$246
- VRAYLAR$231
- KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT$137
- LIVTENCITY$125
- Symbravo$114
- BREZTRI$108
- Veozah$101
How this compares
$3,379 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 14 | $75 |
| Montelukast Sodium | 12 | $73 |
| Azithromycin | 21 | $45 |
Paid to pharmacies, not to this prescriber.
Other family in Largo
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.